key: cord-0727153-fg33uy9z authors: Beys-da-Silva, Walter Orlando; da Rosa, Rafael Lopes; Santi, Lucélia; Tureta, Emanuela Fernanda; Terraciano, Paula Barros; Guimarães, Jorge Almeida; Passos, Eduardo Pandolfi; Berger, Markus title: The risk of COVID-19 for pregnant women: Evidences of molecular alterations associated with preeclampsia in SARS-CoV-2 infection date: 2020-11-01 journal: Biochim Biophys Acta Mol Basis Dis DOI: 10.1016/j.bbadis.2020.165999 sha: 59d3e5f8bf885fd3e226083359b08ca025cc6ed5 doc_id: 727153 cord_uid: fg33uy9z nan The infection is caused by a new enveloped RNA β-coronavirus, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which can primarily infect type II alveolar epithelial cells of the lung through the binding to a specific receptor, angiotensin converting enzyme-2 (ACE-2) 2 . Since ACE-2 is widely expressed in different tissues, several extrapulmonary sites, such as heart, blood vessels, kidney, intestine, brain and placenta can be affected by the virus 3 . It is well known that physiological and immunological changes during pregnancy can mask or even increase the susceptibility to respiratory infections. Changes including increased heart rate, altered pulmonary volumes, as well as the natural physiological shift to a T-helper 2 response (Th2) which attenuates the cell-mediated immunity by Th1 system, leaving the mother vulnerable to viral infections 1 . In fact, adverse outcomes showing increased risk of maternal morbidity and mortality when compared to non-pregnant women have been demonstrated during the outbreaks caused by influenza virus and also other two coronavirus strains, the severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) 4 . Regarding SARS-CoV-2 infection, the prevailing symptoms in pregnant women are cough, dyspnea, fever, chest pain and lymphopenia 4 . Similar to non-pregnant patients, severe cases evolve to pneumonia and vascular-related complications such as thrombocytopenia, elevated D-dimer levels and microthrombus formation 5, 6 . Recently, two systematic reviews, infection or even cases of patients that developed these pathological conditions during the course of infection (for details see Table S1 ). Accordingly, a series of 116 cases identified 4.3 % of patients with hypertensive disorders, including 3.4 % with preeclampsia 7 . Prabhu et al (2020) 8 reported an incidence of preeclampsia in 15.7 % in SARS-CoV-2 positive patients versus 9.3 % in negative patients (Table S1 ). Evidence of fetal vascular malperfusion was noted among 48.3 % positive placentas, while 11.3 % placentas presented this condition among women without COVID-19. These placentas were noted to have thrombi in the fetal vessels. Moreover, Shanes et al (2020) 9 analysing 16 placentas from patients infected with SARS-CoV-2, found an increased prevalence of decidual arteriopathy and maternal vascular malperfusion, a pattern of placental injury which can be directly associated to hypertensive disorders, preeclampsia and abnormalities in oxygenation within the intervillous space. Since clinical evidence pointed to a correlation between COVID-19 and preeclampsia disease we performed the search for molecular alterations promoted by SARS-CoV-2 infection that might be linked to this clinical outcome. For this purpose, host Differentially Expressed Genes (DEGs) from clinical and experimental datasets of SARS-CoV-2 infection were obtained from published data [10] [11] [12] . Further, those host DEGs were checked to potential assignment to genes associated with preeclampsia disease found in the MalaCards Human Disease Database (https://www.malacards.org) 13 . The assignment checking was made manually for each DEG against all genes associated with preeclampsia in MalaCards Database. Afterwards, a Gene Set Enrichment Analysis (GSEA) of the DEGs linked to preeclampsia was also performed with the Reactome bioinformatics resource (https://reactome.org/), to identify classes of genes that are over-represented in a set of pathways 14 , and may have an association with preeclampsia. A gene set was considered significantly enriched with FDR < 0.25 for the normalized enrichment score (NES). The network presented in Figure 1 was constructed, visualized and analyzed by using the Cytoscape 3.8.2 software (Cytoscape Apps) 10 15 . Interestingly, our data indicated that SARS-CoV-2 infection altered the expression of several biomarkers involved in preeclampsia (Fig. 1) . Also, it was found classes of genes/proteins related to the four main molecular pathways involved in this disease, such as (Table S2) (Table S2) . Similarly, endoglins (ENG) also has potent anti-VEGF activity acting synergistically contributing to hypertension, proteinuria, and endothelial cell dysfunction associated with preeclampsia 16 . Corroborating our results, Mendoza et al (2020) 17 showed that all cases of infected pregnant women developing preeclampsia features had increased serum levels of FLT-1/PGF (Table S1 ). The worst case had FLT-1/PGF ≥85/110, does not resolve spontaneously and delivery was the only definitive cure. Their overall conclusion was that COVID-19 can induce a preeclampsia-like syndrome 17 . According to Shanes et al (2020) 9 (Fig. 1, Table S2 ). Even proinflammatory cytokines such as IL-6 can have a central role inducing tissue factor expression, stimulating angiotensin system and then contributing to hypercoagulation and reduced placental blood perfusion 18 . Altogether these events lead to a decrease in oxygen supply, triggering ischemia/hypoxia-related signaling and changes in oxidative stress markers (HIF-1A, OLR1, CAT, HMOX1). In fact, markers of cellular oxygen deprivation such as hypoxia-inducible factors (HIF-1A and 2A) are expressed in proliferative trophoblasts and in the placentas of women with preeclampsia 19 . Preclinical data already detected that HIF-1A overexpression in pregnant mice is associated with hypertension, proteinuria, and fetal growth restriction 16 . In summary, COVID-19 pandemic is the most important health challenge in the world nowadays. Pregnant women are susceptible individuals that requires a differential care during an outbreak, mainly because of their altered immunological and physiological response which increases their susceptibility to infections and other clinical conditions. Although pathogenesis is far to be understood, the ongoing clinical data suggest an association between J o u r n a l P r e -p r o o f Journal Pre-proof SARS-CoV-2 infection and the increase in potential life-threatening conditions to pregnant women and their infants, such as preeclampsia. Our data analysis supports these clinical evidences indicating that SARS-CoV-2 can affect different molecular pathways related to preeclampsia disease such as angiogenesis, hypoxia, inflammatory signalling, hypercoagulation and imbalance of vasoactive peptides. Thus, pregnant women are a higher risk population and antenatal surveillance for women with COVID-19 should be a priority. COVID-19, coronavirus, preeclampsia, pregnant women; SARS-CoV-2 All authors reviewed the research letter and contributed substantially. The authors also would like to declare that there is no conflict of interest involved in this work. Coronavirus disease 2019 (COVID-19) pandemic and pregnancy Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis Pregnancy and Perinatal Outcomes of Women With Coronavirus Disease (COVID-19) Pneumonia: A Preliminary Analysis COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up Coronavirus disease 2019 in pregnant women: a report Placental Pathology in COVID-19 Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19 Proteomics of SARS-CoV-2-infected host cells reveals therapy targets MalaCards: An amalgamated human disease compendium with diverse clinical and genetic annotation and structured search The reactome pathway knowledgebase Cytoscape: A software Environment for integrated models of biomolecular interaction networks Preeclampsia: Pathophysiology, Challenges, and Perspectives Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study